BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 15709746)

  • 1. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
    Baskakov IV; Bocharova OV
    Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
    Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
    Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation.
    Breydo L; Bocharova OV; Makarava N; Salnikov VV; Anderson M; Baskakov IV
    Biochemistry; 2005 Nov; 44(47):15534-43. PubMed ID: 16300402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into alternate aggregated prion protein forms.
    Polano M; Bek A; Benetti F; Lazzarino M; Legname G
    J Mol Biol; 2009 Nov; 393(5):1033-42. PubMed ID: 19720066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for conversion of prion protein into amyloid fibrils.
    Breydo L; Makarava N; Baskakov IV
    Methods Mol Biol; 2008; 459():105-15. PubMed ID: 18576151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Branched chain mechanism of polymerization and ultrastructure of prion protein amyloid fibrils.
    Baskakov IV
    FEBS J; 2007 Aug; 274(15):3756-65. PubMed ID: 17617227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core structure of amyloid fibrils formed by residues 106-126 of the human prion protein.
    Walsh P; Simonetti K; Sharpe S
    Structure; 2009 Mar; 17(3):417-26. PubMed ID: 19278656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231).
    Martins SM; Frosoni DJ; Martinez AM; De Felice FG; Ferreira ST
    J Biol Chem; 2006 Sep; 281(36):26121-8. PubMed ID: 16844683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions.
    Lührs T; Zahn R; Wüthrich K
    J Mol Biol; 2006 Mar; 357(3):833-41. PubMed ID: 16466741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reconstitution of mammalian prion infectivity de novo.
    Baskakov IV
    FEBS J; 2007 Feb; 274(3):576-87. PubMed ID: 17288547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrogen/deuterium exchange mass spectrometry identifies two highly protected regions in recombinant full-length prion protein amyloid fibrils.
    Nazabal A; Hornemann S; Aguzzi A; Zenobi R
    J Mass Spectrom; 2009 Jun; 44(6):965-77. PubMed ID: 19283723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids.
    Jones EM; Surewicz WK
    Cell; 2005 Apr; 121(1):63-72. PubMed ID: 15820679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro assay for fragmentation of amyloid fibers of yeast prion protein.
    Inoue Y; Yoshida M
    Methods; 2006 May; 39(1):56-60. PubMed ID: 16750392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
    Breydo L; Bocharova OV; Baskakov IV
    Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid formation of amyloid from alpha-monomeric recombinant human PrP in vitro.
    Tahiri-Alaoui A; James W
    Protein Sci; 2005 Apr; 14(4):942-7. PubMed ID: 15741327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autocatalytic conversion of recombinant prion proteins displays a species barrier.
    Baskakov IV
    J Biol Chem; 2004 Feb; 279(9):7671-7. PubMed ID: 14668351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process.
    Lee S; Eisenberg D
    Nat Struct Biol; 2003 Sep; 10(9):725-30. PubMed ID: 12897768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysozyme amyloidogenesis is accelerated by specific nicking and fragmentation but decelerated by intact protein binding and conversion.
    Mishra R; Sörgjerd K; Nyström S; Nordigården A; Yu YC; Hammarström P
    J Mol Biol; 2007 Feb; 366(3):1029-44. PubMed ID: 17196616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.